Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
ABBV | NYSE | USD | Real-time | |
0QCV | London | EUR | Real-time | |
ABBV | BIVA | MXN | Delayed | |
ABBV | Mexico | MXN | Delayed | |
1ABBV | Milan | EUR | Real-time | |
4AB | TradeGate | EUR | Delayed | |
4AB | Frankfurt | EUR | Delayed | |
ABBV34 | B3 | BRL | Delayed | |
ABBV | Vienna | EUR | Real-time | |
ABBV | Lima | USD | Delayed |
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
---|---|---|---|---|---|
Moving Averages | Buy | Buy | Buy | Buy | Buy |
Technical Indicators | BUY | Strong Buy | Strong Buy | Strong Sell | Strong Buy |
Summary | Buy | Strong Buy | Strong Buy | Neutral | Strong Buy |
Filter Table By:
Pattern | Timeframe | Reliability | Candles Ago | Candle Time | |
---|---|---|---|---|---|
Emerging Patterns | |||||
Belt Hold Bullish | 15 | Current | |||
Bullish Engulfing | 15 | Current | |||
Belt Hold Bullish | 30 | Current | |||
Bullish Engulfing | 30 | Current | |||
Bullish Engulfing | 1H | Current | |||
Completed Patterns | |||||
Engulfing Bearish | 30 | 1 | Apr 25, 2024 20:00 | ||
Tri-Star Bearish | 1D | 2 | Apr 22, 2024 | ||
Engulfing Bearish | 5H | 2 | Apr 24, 2024 18:00 |
Exchange | Last | Bid | Ask | Volume | Change % | Currency | Time | ||
---|---|---|---|---|---|---|---|---|---|
NYSE | 163.40 | 0.00 | 0.00 | 2,058,684 | -2.33% | USD | |||
London | 163.03 | 155.30 | 171.24 | 1,252 | -2.11% | EUR | |||
BIVA | 2,880.00 | 0.00 | 0.00 | 0 | 0.00% | MXN | |||
Mexico | 2,880.00 | 0.00 | 0.00 | 0 | +0.00% | MXN | |||
Milan | 156.44 | 0.00 | 0.00 | 263 | +1.20% | EUR | |||
TradeGate | 150.00 | 150.40 | 150.82 | 3,643 | -3.38% | EUR | |||
Frankfurt | 149.98 | 150.42 | 150.88 | 47 | -4.86% | EUR | |||
B3 | 51.75 | 51.45 | 51.80 | 84 | -3.63% | BRL | |||
Vienna | 164.70 | 161.00 | 164.70 | 0 | +0.00% | EUR | |||
Lima | 168.80 | 0.00 | 0.00 | 18 | 0.00% | USD |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
---|---|---|---|---|---|---|---|---|---|
Barclays | 204.20 | 204.85 | 199.08 | +0.20 | +0.10% | 34.33M | |||
AstraZeneca | 11,945.0 | 12,144.0 | 11,882.0 | -81.0 | -0.67% | 933.91K | 15:20:56 | ||
Legal & General | 235.10 | 236.69 | 234.18 | +2.30 | +0.99% | 10.11M | |||
Rolls-Royce Holdings | 417.80 | 418.90 | 409.20 | +12.10 | +2.98% | 12.31M | |||
Anglo American | 2,651.5 | 2,721.0 | 2,518.5 | +91.5 | +3.57% | 7.79M | 15:20:46 | ||
Lloyds Banking | 52.38 | 52.60 | 51.08 | +1.18 | +2.31% | 82.70M | |||
IAG | 177.35 | 179.00 | 176.80 | +1.20 | +0.68% | 6.05M | |||
NatWest Group | 306.40 | 308.70 | 295.50 | +16.60 | +5.73% | 24.16M | 15:20:48 | ||
HSBC | 664.80 | 665.80 | 661.10 | +2.90 | +0.44% | 5.35M | |||
BAE Systems | 1,340.00 | 1,340.00 | 1,307.00 | +19.50 | +1.48% | 3.29M |
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn’s disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Read MoreAre you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review